A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets

Inclusion Criteria: * Able to understand, sign and date the informed consent form * Male or female 18 to 55 years old with a diagnosis of epilepsy who are stable * Body mass 18 to 34 kg/m, inclusive * Is continuously receiving a fixed dose of their AED medication(s)for a minimum of 30 days prior to screening * Stay on the same dosages of their routine concomitant medications throughout the study * Healthy, as determined by pre-study medical history, vital signs, physical exam, ECG and the opinion of the investigator * Normal renal function per laboratory test * No clinically relevant labs. * Negative for hepatitis B, C and HIV * For females, negative pregnancy test * Negative for drugs of abuse and alcohol * Nonsmoker or has not smoked within the past six months. * Some over-the-counter medications may be permitted at the discretion of the investigator * Able to communicate well and comply with study procedures, requirements and restrictions Exclusion Criteria: * History or presence of clinically significant medical disorders * Have a current psychiatric disorder * History of status epilepticus within 90 days of screening * Any other condition that the investigator would feel could interfere with the safety of the subject or the study protocol. * Taking three or more AED medications * Use of felbamate, aspirin, carbapenem antibiotics, rifampin, ritonavir, macrolide antibiotics, cholestyramine, and/or risperidone. * Use of any investigational agent or medical device within 30 days of screening. * History of clinically significant drug allergy that in the opinion of the investigator may compromise the subject's safety or study results. * History of known hypersensitivity to divalproex sodium or its excipients * History of alcohol or drug abuse or dependence in the past 5 years * Consumed alcohol, caffeine or other xanthine-containing foods or beverages within 48 hours prior to each clinic admission. * Consumed grapefruit and/or grapefruit containing products within days prior to admission to the clinic on Day -1 and they agree not to consume grapefruit and/or grapefruit containing products for the duration of their study involvement * Participated in any strenuous physical exercise within 72 hours before admission to the clinic on Day 1 and agrees to abstain from the duration of their study involvement. * Acute illness at screening and/or at admission to the clinic * Lactose intolerance or unusual dietary habits. * Blood donation within 8 weeks of admission to this study